ReviewFrontiers in oncology2021

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer.

Neil Portman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.